HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

Wendy B. C. Stevens*, Katerina Bakunina, Marloes Cuijpers, Martine Chamuleau, Aart Beeker, Rob Fijnheer, Holger Hebart, Hein P. J. Visser, Jeanette K. Doorduijn, Kim Linton, Martin Dreyling, Daphne de Jong, Marie José Kersten

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

Original languageEnglish
Article numbere325
Issue number1
Publication statusPublished - 2020

Cite this